Literature DB >> 26604148

Mitochondrial defects and neurodegeneration in mice overexpressing wild-type or G399S mutant HtrA2.

Nicolas Casadei1, Poonam Sood2, Thomas Ulrich3, Petra Fallier-Becker4, Nicole Kieper5, Stefan Helling6, Caroline May6, Enrico Glaab7, Jing Chen6, Silke Nuber1, Hartwig Wolburg, Katrin Marcus6, Doron Rapaport3, Thomas Ott8, Olaf Riess1, Rejko Krüger9, Julia C Fitzgerald10.   

Abstract

The protease HtrA2 has a protective role inside mitochondria, but promotes apoptosis under stress. We previously identified the G399S HtrA2 mutation in Parkinson's disease (PD) patients and reported mitochondrial dysfunction in vitro. Mitochondrial dysfunction is a common feature of PD and related to neurodegeneration. Complete loss of HtrA2 has been shown to cause neurodegeneration in mice. However, the full impact of HtrA2 overexpression or the G399S mutation is still to be determined in vivo. Here, we report the first HtrA2 G399S transgenic mouse model. Our data suggest that the mutation has a dominant-negative effect. We also describe a toxic effect of wild-type (WT) HtrA2 overexpression. Only low overexpression of the G399S mutation allowed viable animals and we suggest that the mutant protein is likely unstable. This is accompanied by reduced mitochondrial respiratory capacity and sensitivity to apoptotic cell death. Mice overexpressing WT HtrA2 were viable, yet these animals have inhibited mitochondrial respiration and significant induction of apoptosis in the brain leading to motor dysfunction, highlighting the opposing roles of HtrA2. Our data further underscore the importance of HtrA2 as a key mediator of mitochondrial function and its fine regulatory role in cell fate. The location and abundance of HtrA2 is tightly controlled and, therefore, human mutations leading to gain- or loss of function could provide significant risk for PD-related neurodegeneration.
© The Author 2015. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26604148     DOI: 10.1093/hmg/ddv485

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  8 in total

Review 1.  Mechanisms of Gene-Environment Interactions in Parkinson's Disease.

Authors:  Sheila M Fleming
Journal:  Curr Environ Health Rep       Date:  2017-06

Review 2.  Current perspective of mitochondrial biology in Parkinson's disease.

Authors:  Navneet Ammal Kaidery; Bobby Thomas
Journal:  Neurochem Int       Date:  2018-03-14       Impact factor: 3.921

Review 3.  Mitochondrial Quality Control Proteases in Neuronal Welfare.

Authors:  Roman M Levytskyy; Edward M Germany; Oleh Khalimonchuk
Journal:  J Neuroimmune Pharmacol       Date:  2016-05-02       Impact factor: 4.147

Review 4.  The HSP90 Family: Structure, Regulation, Function, and Implications in Health and Disease.

Authors:  Abdullah Hoter; Marwan E El-Sabban; Hassan Y Naim
Journal:  Int J Mol Sci       Date:  2018-08-29       Impact factor: 5.923

Review 5.  Unraveling the Dichotomy of Enigmatic Serine Protease HtrA2.

Authors:  Ayon Chakraborty; Roshnee Bose; Kakoli Bose
Journal:  Front Mol Biosci       Date:  2022-02-03

Review 6.  Gut Microbial Metabolites in Parkinson's Disease: Implications of Mitochondrial Dysfunction in the Pathogenesis and Treatment.

Authors:  Yixuan Liang; Li Cui; Jiguo Gao; Mingqin Zhu; Ying Zhang; Hong-Liang Zhang
Journal:  Mol Neurobiol       Date:  2021-04-06       Impact factor: 5.590

7.  Oligomeric assembly regulating mitochondrial HtrA2 function as examined by methyl-TROSY NMR.

Authors:  Yuki Toyama; Robert W Harkness; Tim Y T Lee; Jason T Maynes; Lewis E Kay
Journal:  Proc Natl Acad Sci U S A       Date:  2021-03-16       Impact factor: 12.779

8.  Mitochondrial HTRA2 Plays a Positive, Protective Role in Dictyostelium discoideum but Is Cytotoxic When Overexpressed.

Authors:  Suwei Chen; Oana Sanislav; Sarah J Annesley; Paul R Fisher
Journal:  Genes (Basel)       Date:  2018-07-16       Impact factor: 4.096

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.